ArticlePhotochemistry and photobiology
Liquid metal nanoparticles for enhanced delivery of benzoporphyrin derivative in photodynamic cancer therapy.
Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liquid metal nanoparticles for enhanced delivery of benzoporphyrin derivative in photodynamic cancer therapy.Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Photodynamic therapy (PDT) is a targeted cancer treatment offering precise tumor ablation with minimal systemic toxicity. However, its clinical application is constrained by poor solubility, rapid clearance, and inadequate tumor accumulation of photosensitizers (PS). This study presents an innovative liquid metal nanoparticle (LMNP) platform, composed of gallium-indium eutectic alloy (EGaIn), engineered to address these drug delivery challenges in PDT. Using a one-step sonication process, EGaIn nanoparticles are synthesized and functionalized with folic acid (FA) for tumor-specific targeting, beta cyclodextrin (β-CD) for enhanced drug encapsulation, and benzoporphyrin derivative (BPD) as a PS. The inclusion of β-CD significantly improves the BPD loading capacity, achieving a three-fold enhancement (52% vs. 18%) while ensuring nanoparticle stability and sustained drug release. Covalent binding of FA and β-CD to the gallium oxide surface enables effective targeting and biocompatibility. In vitro analyses demonstrate potent PDT efficacy, even with reduced cellular uptake, underscoring the platform's ability to overcome intracellular delivery barriers. This LMNP-based nanoplatform addresses critical PDT limitations, such as suboptimal drug delivery and systemic toxicity, leveraging the unique chemical and physical properties of EGaIn nanoparticles. Its multifunctional design integrates targeted delivery, controlled release, and precise therapeutic activation, representing a promising advancement in the development of effective, personalized cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.